{Reference Type}: Journal Article
{Title}: A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
{Author}: Miao Q;Nguyen W;Zhu J;Liu G;van Oers MM;Tang B;Yan K;Larcher T;Suhrbier A;Pijlman GP;
{Journal}: Vaccine
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 13
{Factor}: 4.169
{DOI}: 10.1016/j.vaccine.2024.07.037
{Abstract}: Getah virus (GETV) is an emerging mosquito-borne virus with economic impact on the livestock industry in East Asia. In this study, we successfully produced GETV virus-like particles (VLPs) in insect cells using the baculovirus expression vector system. We show that the GETV envelope glycoproteins were successfully expressed at the surface of the insect cell and were glycosylated. VLPs were isolated from the culture fluid as enveloped particles of 60-80 nm in diameter. Two 1 µg vaccinations with this GETV VLP vaccine, without adjuvant, generated neutralizing antibody responses and protected wild-type C57/BL6 mice against GETV viremia and arthritic disease. The GETV VLP vaccine may find application as a horse and/or pig vaccine in the future.